{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:50:32Z","timestamp":1782118232550,"version":"3.54.5"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ajo.2026.01.042","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:52:21Z","timestamp":1770684741000},"page":"343-344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comment On: Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists; An Examination of the FAERS Database"],"prefix":"10.1016","volume":"285","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-6368","authenticated-orcid":false,"given":"V\u00edctor Manuel Asensio","family":"S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.01.042_bib0001","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2025.12.015","article-title":"Potential eye disorders in people with and without type 2 diabetes mellitus exposed to GLP-1 receptor agonists: an examination of the FAERS database","volume":"283","author":"Murray","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.01.042_bib0002","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ajo.2026.01.042_bib0003","first-page":"136","article-title":"Signal detection in the FDA adverse event reporting system: a review of statistical methods","volume":"26","author":"Alatawi","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ajo.2026.01.042_bib0004","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/archopht.116.7.874","article-title":"Early worsening of diabetic retinopathy in the diabetes control and complications trial","volume":"116","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2026.01.042_bib0005","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in Type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2026.01.042_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamainternmed.2014.1824","article-title":"National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries","volume":"174","author":"Lipska","year":"2014","journal-title":"JAMA Intern Med"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:22:11Z","timestamp":1782116531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":6,"alternative-id":["S0002939426000619"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.042","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment On: Potential Eye Disorders in People With and Without Type 2 Diabetes Mellitus Exposed to GLP-1 Receptor Agonists; An Examination of the FAERS Database","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.01.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}